Clinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator

MT Newswires Live

Dec 02, 2025

Clinuvel Pharmaceuticals (ASX:CUV) confirmed a mid-2026 target to file its NEURACTHEL Instant therapy candidate, a generic injectable adrenocorticotropic hormone formulation, with a European regulatory authority via a national procedure, according to a Tuesday Australian bourse filing.

It validated the end-to-end Good Manufacturing Practice processes for NEURACTHEL Instant. Three consecutive batches were produced, confirming a reproducible and reliable process. This stock is now available for clinical use, pending regulatory approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588880670"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588880670\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588880670?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 10:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588880670","market":"sh","top_or_hot":-1,"title":"Clinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) confirmed a mid-2026 target to file its NEURACTHEL Instant therapy candidate, a generic injectable adrenocorticotropic hormone formulation, with a European regulatory authority via a national procedure, according to a Tuesday Australian bourse filing.</p><p>It validated the end-to-end Good Manufacturing Practice processes for NEURACTHEL Instant. Three consecutive batches were produced, confirming a reproducible and reliable process. This stock is now available for clinical use, pending regulatory approval.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-02 10:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> (ASX:CUV) confirmed a mid-2026 target to file its NEURACTHEL Instant therapy candidate, a generic injectable adrenocorticotropic hormone formulation, with a European regulatory authority via a national procedure, according to a Tuesday Australian bourse filing.</p><p>It validated the end-to-end Good Manufacturing Practice processes for NEURACTHEL Instant. Three consecutive batches were produced, confirming a reproducible and reliable process. This stock is now available for clinical use, pending regulatory approval.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588880670","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588880670","pubTimestamp":1764643778,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Clinuvel Pharmaceuticals (ASX:CUV) confirmed a mid-2026 target to file its NEURACTHEL Instant therapy candidate, a generic injectable adrenocorticotropic hormone formulation, with a European regulator","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7067":"生物科技"},"translate_title":"Clinuvel确认2026年中期向欧洲监管机构提交促肾上腺皮质激素制剂疗法候选物的目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":1},"content_text":"Clinuvel Pharmaceuticals (ASX:CUV) confirmed a mid-2026 target to file its NEURACTHEL Instant therapy candidate, a generic injectable adrenocorticotropic hormone formulation, with a European regulatory authority via a national procedure, according to a Tuesday Australian bourse filing.It validated the end-to-end Good Manufacturing Practice processes for NEURACTHEL Instant. Three consecutive batches were produced, confirming a reproducible and reliable process. This stock is now available for clinical use, pending regulatory approval.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}